Minimal Disease Activity as A New Therapeutic Target in Atopic Dermatitis: A 5‐Year Real‐Life Experience With Dupilumab
Our long-term real-world data support the sustained effectiveness and safety of dupilumab in moderate-to-severe AD, with over 55% of patients achieving and maintaining MDA at 5 years.
Authors
- Giovanni Cavaliere
- L. Mastorino
- M. Ortoncelli
- Niccolò Siliquini (ORCID: https://orcid.org/0000-0002-1215-5910)
- David Favre (ORCID: https://orcid.org/0000-0002-0231-114X)
- Chiara Anna Fiasconaro
- Federico Goso
- Francesco Leo
- Pietro Quaglino
- Yingying Liao
- Luca Cangialosi
Institutions
- University of Turin (IT)
Publication Details
- Journal
- International Journal of Dermatology
- Published
- 2026-01-13
- DOI
- https://doi.org/10.1111/ijd.70260
- Primary Topic
- Dermatology and Skin Diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00